Grammidin NEO with anesthetic lozenges No. 18

Grammidin NEO with anesthetic lozenges No. 18

A country

Russia
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.

Active substance

Gramicidin C + Oxybuprocaine + Cetylpyridinium chloride

Compound

Gramicidin C, oxybuprocaine, cetylpyridinium chloride.

pharmachologic effect

Antibacterial combined drug for local use in the oral cavity and pharynx. The drug contains the antibiotic gramicidin C, the local anesthetic oxybuprocaine and the antiseptic cetylpyridinium chloride. The drug has a pronounced antibacterial effect against pathogens of infectious and inflammatory diseases of the pharynx and oral cavity. Increases the permeability of the microbial cell membrane, which disrupts its barrier functions and leads to its death. The anesthetic oxybuprocaine, causing a reversible block of axonal conduction of nerve impulses, has an analgesic effect on the mucous membrane of the oral cavity and pharynx. Cetylpyridinium chloride, being an antiseptic, inhibits the growth and reproduction of pathogens of infectious diseases of the oral cavity. The drug has antimicrobial, analgesic and anti-inflammatory effects, reduces discomfort in the oral cavity and pharynx, and facilitates the swallowing process. When absorbed, the drug stimulates hypersalivation, which promotes mechanical cleansing of the oral cavity and pharynx from microorganisms. The drug has a local effect.

Indications for use

Infectious and inflammatory diseases of the oral cavity and pharynx: sore throat, pharyngitis, tonsillitis, periodontal disease, gingivitis, stomatitis.

Mode of application

For adults and children over 12 years of age, the drug is prescribed 1 tablet 3-4 times a day; children aged 4 to 12 years - 1 tablet 1-2 times a day. The tablets are used after meals, dissolving in the mouth without chewing. Immediately after using the drug, you should refrain from eating and drinking for 1-2 hours. If there is no therapeutic effect within 7 days of taking the drug, the patient should consult a doctor.

Interaction

The drug, when taken together, increases the effectiveness of other antimicrobial agents of local and systemic action.

Side effect

In some cases: allergic reactions, temporary loss of sensitivity of the tongue.

Contraindications

I trimester of pregnancy, children under 4 years of age, hypersensitivity to the components of the drug.

Overdose

No data.

special instructions

No data.

Grammidin Neo tablets for rassas No. 18

Compound

Active substances:

Excipients: colloidal silicon dioxide - 5 mg, talc - 60 mg, acesulfame potassium - 15 mg, mint flavor - 25 mg, sorbitol - 1065.75 mg, magnesium stearate - 25 mg.

Indications for use

Infectious and inflammatory diseases of the oral cavity and pharynx: sore throat; pharyngitis; tonsillitis; periodontal disease; gingivitis; stomatitis.

Contraindications

• Hypersensitivity to the components included in the drug;
• children under 4 years of age;
• pregnancy (first trimester).

Directions for use and doses

It is used after meals, by dissolving in the mouth without chewing.

Immediately after using the drug, you should refrain from eating and drinking for 1-2 hours.

Dosage for adults and children over 12 years of age: 1 tablet 3-4 times a day.

Dosage for children from 4 to 12 years: 1 tablet 1-2 times a day.

If there is no therapeutic effect within 7 days of taking the drug, it is recommended to consult a doctor.

Storage conditions

At a temperature not higher than 25 °C. Keep out of the reach of children

Best before date

2 years. Do not use after expiration date

Description

Antibiotic + antiseptic.

Use in children

Contraindication: children under 4 years of age.

Pharmacodynamics

Combined drug for local use.

Gramicidin C is an antimicrobial agent. The mechanism of action is associated with an increase in the permeability of the cytoplasmic membrane of the microbial cell, which violates its stability and causes cell death. Gramicidin C has a pronounced antimicrobial effect against pathogens of infectious diseases of the oral cavity and pharynx.

Cetylpyridinium chloride is an antiseptic. Suppresses the growth and reproduction of pathogens of infectious diseases of the oral cavity.

The combined drug reduces inflammation, has an antimicrobial effect, softens discomfort in the throat, facilitates swallowing, and when absorbed causes hypersalivation, which promotes mechanical cleansing of the oral cavity and pharynx from microorganisms.

Side effects

In some cases, allergic reactions to the components of the drug are possible

Use during pregnancy and breastfeeding

It is not recommended to use the drug during pregnancy (I) trimester. Breastfeeding should be stopped while taking the drug.

Interaction

Grammidin® neo enhances the effects of other local and systemic antimicrobial agents

Grammidin lozenges 1.5 mg package No. 20

Grammidin for children General characteristics: international nonproprietary name - Gramicidin C + Cetylpyridinium chloride.

Description - tablets are white or almost white, round, biconvex, bevelled, with GR embossed on one side and raspberry flavor. Minor marbling is allowed.

Composition of the drug One tablet contains the active substances: gramicidin C - 1.50 mg (in the form of gramicidin C dihydrochloride - 1.60 mg), cetylpyridinium chloride - 1.00 mg (in the form of cetylpyridinium chloride monohydrate - 1.05 mg). excipients: colloidal silicon dioxide (Aerosil 200), talc, citric acid monohydrate, aspartame, raspberry flavor, sorbitol (Neosorb), magnesium stearate.

Release form Lozenges 1.5 mg + 1 mg

Pharmacotherapeutic group antibiotic + antiseptic Code ATX [R02AA20]

Pharmacological properties Combined drug for the symptomatic treatment of infectious and inflammatory diseases of the throat and oral cavity. The drug contains the antimicrobial agent gramicidin C and the antiseptic agent cetylpyridinium chloride. The mechanism of action of gramicidin C is associated with an increase in the permeability of the cytoplasmic membrane of the microbial cell, which disrupts its stability and causes death. Gramicidin C has an antibacterial (bactericidal) effect against a wide range of gram-positive and gram-negative microorganisms. Cetylpyridinium chloride is an antiseptic that inhibits the growth and reproduction of pathogens that cause infectious diseases in the oral cavity. The drug has an antimicrobial effect, reduces inflammation, softens discomfort in the throat, facilitates swallowing, and when absorbed causes hypersalivation, which contributes to the mechanical cleansing of the oral cavity and pharynx from microorganisms.

Indications for use Symptomatic treatment of infectious and inflammatory diseases of the oral cavity and throat, accompanied by pain in the throat and oral cavity: pharyngitis, tonsillitis, periodontitis, gingivitis, stomatitis.

Method of administration and dosage Locally. Used after meals, by dissolving in the mouth without chewing. Immediately after using the drug, you should refrain from eating and drinking for 1-2 hours. Dosage for children from 6 to 12 years: 1 tablet 4 times a day. The maximum daily dose is 4 tablets. Dosage for children over 12 years of age and adults: 2 tablets (one after the other for 20-30 minutes) 4 times a day. The maximum daily dose is 8 tablets. If there is no therapeutic effect within 7 days of taking the drug, it is recommended to consult a doctor.

Side effects Possible allergic reactions to the components of the drug, gastrointestinal disorders (nausea, diarrhea).

Contraindications - hypersensitivity to the components of the drug - phenylketonuria (the drug contains aspartame) - lactation period - children under 6 years of age

Overdose Symptoms: taking the drug in doses higher than recommended may cause disturbances in the gastrointestinal tract due to changes in the bacterial microflora: nausea, vomiting, diarrhea. Treatment: You should stop taking the drug and consult a doctor.

Precautionary measures Special instructions Grammidin for children should not be taken in the presence of open wounds in the oral cavity, since cetylpyridinium chloride slows down wound healing. Pregnancy and lactation Pregnant women should consult a doctor before using the drug. The use of the drug is possible if the potential benefit to the mother outweighs the possible risk to the fetus. Breastfeeding should be stopped during treatment.

Influence on the ability to drive vehicles and operate machinery. The drug does not affect the performance of potentially hazardous activities that require special attention and quick reactions (driving a car and other vehicles, working with moving mechanisms, working as a dispatcher and operator, etc.).

Interaction with other drugs Currently, there are no cases of clinically significant interactions with other drugs.

Conditions and shelf life Store in a place protected from light at a temperature not exceeding 25 C. Keep out of the reach of children! Shelf life 2 years. Do not use after expiration date.

Conditions for dispensing without a prescription.

Packaging 9 tablets in a blister pack made of polyvinyl chloride film and printed varnished aluminum foil. 2 blister packs along with instructions for use are placed in a cardboard pack.

Grammidin with anesthetic Neo lozenges No. 9x2

Name

Grammidin with anesthetic Neo tab. dras. in the contact cell. №9x2

Description

The tablets are white, round, biconvex, with the inscription GR on one side.

Compound

1 tablet contains: Active substances: gramicidin C – 3.00 mg (in the form of gramicidin C dihydrochloride – 3.20 mg), oxybuprocaine hydrochloride – 0.20 mg, cetylpyridinium chloride – 1.00 mg (in the form of cetylpyridinium chloride monohydrate – 1 .05 mg). Excipients: colloidal silicon dioxide – 5.00 mg, talc – 60.00 mg, acesulfame potassium – 15.00 mg, mint flavor – 25.00 mg, sorbitol – 1065.55 mg, magnesium stearate – 25.00 mg.

Pharmacotherapeutic group

Means for the treatment of diseases of the larynx and pharynx. Other antiseptics. ATX code:

R02AA20

.

Pharmacological properties

Pharmacodynamics Combined drug for the treatment of infectious and inflammatory diseases of the pharynx and oral cavity. The drug contains the antimicrobial agent gramicidin C, the antiseptic agent cetylpyridinium chloride and the local anesthetic (painkiller) agent oxybuprocaine. The mechanism of action of gramicidin C is associated with an increase in the permeability of the cytoplasmic membrane of the microbial cell, which disrupts its stability and causes cell death. Cetylpyridinium chloride is an antiseptic from the group of quaternary ammonium compounds, has antimicrobial and antifungal (Candida albicans) effects, does not affect mycobacteria. The anesthetic oxybuprocaine has a local anesthetic effect on the mucous membrane of the mouth and throat. Causes a reversible blockade of the propagation and conduction of nerve impulses through the axons of nerve cells. The drug has an antimicrobial effect and helps reduce pain. Pharmacokinetics The drug has a local effect and is practically not absorbed from the gastrointestinal tract.

Indications for use

Local symptomatic treatment of infectious and inflammatory diseases of the oral cavity and pharynx.

Directions for use and doses

It is used after meals, by dissolving in the mouth without chewing. Immediately after using the drug, you should refrain from eating and drinking for 1-2 hours. Dosage for adults and children over 12 years of age: 1 tablet 3-4 times a day. Dosage for children from 6 to 12 years: 1 tablet 1-2 times a day. The drug should not be taken for more than 7 days. If longer-term use is necessary or there is no therapeutic effect (including if the condition worsens), it is recommended to consult a doctor.

Side effect

The frequency of adverse reactions is determined using the following scale: very often (> 1/10), often (> 1/100 to 1/1000 to 1/10000

Contraindications

• hypersensitivity to the components included in the drug;
• children under 6 years of age;
• pregnancy.

Overdose

There is no information about cases of overdose. Considering the amount of active and auxiliary substances contained in 1 tablet, the possibility of overdose is minimal. Symptoms when the recommended doses for cetylpyridinium chloride are exceeded are gastrointestinal disorders (nausea, vomiting, diarrhea). Sorbitol, which is part of the drug, in case of a significant overdose (more than 30 g of sorbitol per day) can cause diarrhea and flatulence. Systemic effects in an overdose of oxybuprocaine may be accompanied by the development of agitation, irritability, asthenia, drowsiness, dizziness, tremor, nausea, vomiting, respiratory failure, bradycardia, atrioventricular block, and in severe cases - convulsions, cardiac arrest, coma. In case of overdose, consult a doctor. Treatment: drug withdrawal, gastric lavage, symptomatic therapy.

Precautionary measures

If during the use of the drug the symptoms of the disease persist or the condition worsens (fever rises, cough, headache, vomiting, etc.), you should consult a doctor. For bacterial infections, in particular those caused by streptococcus, it is recommended to prescribe the main etiotropic therapy with an appropriate systemic antibacterial agent. If a viral infection develops, the use of the drug as monotherapy may not be effective enough, since the viral infection develops intracellularly. It is not recommended to use cetylpyridinium chloride for damage to the mucous membrane due to possible inhibition of repair processes. Patients with contact allergies should not take the drug, as the likelihood of sensitization increases. The use of the drug may temporarily change taste sensations, but within 4 hours after taking the drug, taste perception is restored. It is recommended to take the drug after meals. For some dosage forms of drugs containing cetylpyridinium chloride, it has been shown that their long-term use may cause slight temporary brown discoloration of the teeth and tongue, but these phenomena disappear after discontinuation of the drug. Due to the sorbitol content, the drug is not recommended for patients with congenital fructose intolerance. Due to the sorbitol content, the drug may have a mild laxative effect. Local anesthetics may interfere with the normal coordination of the swallowing reflex, increasing the risk of aspiration of food and water. In this regard, it is not recommended to eat or drink water immediately after using the tablet. Numbness of the tongue and oral mucosa, which may occur with the use of local anesthetics, may increase the risk of injury to the mucous membrane and tongue due to biting. Use in children: Do not use in children under 6 years of age due to the risk of accidental inhalation of the tablet and aspiration.

Use during pregnancy and lactation

The drug is contraindicated for use during pregnancy due to the lack of sufficient data. There is no data on the penetration of active ingredients into breast milk. Taking the drug is not recommended during breastfeeding.

Interaction with other drugs

The activity of cetylpyridinium chloride decreases when it is inactivated by protein and lipid components at the site of inflammation.

Impact on the ability to drive vehicles and operate machinery

Studies to evaluate the effect of the drug on the reaction rate have not been conducted. Based on the profile of adverse reactions, the drug’s effect on the ability to drive a car and operate machinery is not expected.

Conditions and shelf life

In a place protected from light and moisture at a temperature not exceeding 25°C. Keep out of the reach of children. Shelf life: 2 years. Do not use after expiration date.

Vacation conditions

Over the counter.

Package

9 tablets each in a perforated blister pack made of polyvinyl chloride or polyvinyl chloride/polyvinylidene chloride film and printed varnished aluminum foil. 2 contour packages along with instructions for use are placed in a cardboard pack.